Built on Science. Designed for Precision. EVA™ is evidence-led: Accuracy before scale. Personalisation before generalisation. Clinical responsibility at every step.
DNA Interpretation Engine
Built by 70+ experts across medicine, bioinformatics, and AI.
Analyses 200M+ genetic variants with advanced interaction modelling.
Featured in Nature and trusted by 200,000+ users globally.
What This Means
Your DNA sets the context. It shows how your body is likely to respond over time.
Clinical Blood Analysis
DNA shows predisposition. Blood shows reality.
Tested through hospital-grade labs using accredited methods and clinical reference ranges.
Covers metabolism, inflammation, nutrients, and hormones.
What This Means
Confirms what is happening now, not just what is predicted.
Biological Age Modelling
A biological signal of how your body is ageing and functioning.
Built from biomarker patterns like inflammation and metabolic health.
Measured over time, not as a single snapshot.
What This Means
Shows where your biology needs attention and whether your plan is working.
A 12.5-Year Biological Age Reduction Case Study
The Individual
A 44-year-old executive undergoing routine health optimisation showed early biomarker signals linked to cardiovascular risk, chronic inflammation, impaired methylation, and liver stress. Although outwardly healthy, these signals suggested long-term physiological strain that could influence ageing and disease risk over time.
The Approach
The programme used a precision health strategy built on biomarker testing, genetic analysis, personalised nutrition, and targeted supplementation. Interventions focused on correcting the biological pathways driving the abnormal markers and improving overall metabolic balance.
The Outcome
After six months, several biomarkers improved, including markers linked to inflammation, cardiovascular health, and metabolic function. Follow-up testing showed the individual’s biological age had shifted from 44 years to 31.5 years, representing a 12.5-year reduction in biological age.
Explore the Full Case Study
Download the complete clinical report to review the biomarker analysis, intervention strategy, and measured biological changes over time.
Clinical Oversight
Every insight is reviewed by clinicians, not automated systems.
EVA™ supports informed decisions, it does not diagnose.
All protocols are evidence-based and adapted to real-world context.
Laboratory & Testing Standards
Testing is conducted through a global network of trusted laboratories.
All results follow strict quality controls and internationally recognised reference ranges.
At-home convenience with hospital-grade accuracy.
Supplement Quality & Manufacturing
Formulated based on your biology, not trends.
Produced in EU-based, GMP-certified facilities with ISO 22000 and HACCP standards.
GMO-free, gluten-free, vegan, with traceable and bioavailable ingredients.
Evidence - Based Longevity Approach
Longevity should be accessible, not exclusive.
EVA™ makes science-led health practical and usable.
Guided by progress, refined through research and your evolving data.
EVA™ is built on four principles that govern every decision we make:
EVA™ remains science-led, independent, and clinically responsible.
We continuously review emerging research, refine our models, and update recommendations as evidence evolves. Your biology is not static, and neither is our approach. EVA™ communicates like a knowledgeable guide who has already done the research — composed, evidence-based, and discreetly confident.
Disclaimer:
EVA™ is a wellness platform designed to support health optimisation. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider for medical advice. Genetic insights are used to support personalised wellness planning and education. They are not intended to diagnose, treat, cure, or prevent any disease.
Enter your details below to access the complete clinical report — it opens instantly, free.
Join the EVATM waitlist and lock in your founding member discount — applied automatically when the app goes live.
I’m interested in
